These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 28427271

  • 1. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK, Yoo IR, Kim SH, Park SY, O JH, Kang BJ.
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [Abstract] [Full Text] [Related]

  • 2. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S, Trahan TJ, Xiao J, Taghipour M, Mena E, Connolly RM, Subramaniam RM.
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [Abstract] [Full Text] [Related]

  • 3. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK.
    Acta Radiol; 2011 Feb 01; 52(1):21-8. PubMed ID: 21498321
    [Abstract] [Full Text] [Related]

  • 4. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Sakane M, Tatsumi M, Hori M, Onishi H, Tsuboyama T, Nakamoto A, Ota T, Eguchi H, Wakasa K, Hatazawa J, Tomiyama N.
    Eur J Radiol; 2017 Sep 01; 94():64-69. PubMed ID: 28712692
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.
    Cancer; 2013 Jun 01; 119(11):1960-8. PubMed ID: 23504954
    [Abstract] [Full Text] [Related]

  • 10. Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.
    Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, Kaklamani V, Cochet A, Shao Z, Cheng J, Liu G.
    Oncologist; 2020 Apr 01; 25(4):e626-e633. PubMed ID: 32297448
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Han S, Choi JY.
    Breast Cancer Res; 2020 Oct 31; 22(1):119. PubMed ID: 33129348
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
    Kitajima K, Nakatani K, Yamaguchi K, Nakajo M, Tani A, Ishibashi M, Hosoya K, Morita T, Kinoshita T, Kaida H, Miyoshi Y.
    Eur J Nucl Med Mol Imaging; 2018 Sep 31; 45(10):1661-1671. PubMed ID: 29754160
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.
    Oncotarget; 2015 Oct 06; 6(30):29388-95. PubMed ID: 26336821
    [Abstract] [Full Text] [Related]

  • 17. Different 18 F-FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors.
    El-Hennawy G, Moustafa H, Omar W, Elkinaai N, Kamel A, Zaki I, Farid N, El-Kholy E.
    Pediatr Blood Cancer; 2020 Nov 06; 67(11):e28605. PubMed ID: 32706520
    [Abstract] [Full Text] [Related]

  • 18. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
    Li QW, Zheng RL, Ling YH, Wang QX, Xiao WW, Zeng ZF, Fan W, Li LR, Gao YH.
    Abdom Radiol (NY); 2016 Aug 06; 41(8):1448-55. PubMed ID: 27116012
    [Abstract] [Full Text] [Related]

  • 19. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S, Yoshizawa N, Shigekawa T, Takeuchi H, Ogura H, Osaki A, Saeki T, Ueda Y, Yamane T, Kuji I, Sakahara H.
    J Nucl Med; 2016 Aug 06; 57(8):1189-95. PubMed ID: 26940765
    [Abstract] [Full Text] [Related]

  • 20. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M.
    Eur J Cancer; 2014 Jul 06; 50(11):1864-71. PubMed ID: 24841218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.